Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-23 pm EDT 5-day change 1st Jan Change
1.09 USD -0.91% Intraday chart for Akebia Therapeutics, Inc. -4.39% -12.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M MT
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Averoa Seeks EU Approval for Chronic Kidney Disease Drug MT
Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement CI
Sector Update: Health Care Stocks Advance Premarket Thursday MT
Sector Update: Health Care MT
Transcript : Akebia Therapeutics, Inc. - Special Call
Akebia Therapeutics Shares Jump Pre-Bell on FDA Approval of Anemia Treatment for Chronic Kidney Disease Dialysis Patients MT
Akebia Shares Rally Premarket After FDA Approves Vafseo DJ
U.S. FDA approves Akebia's anemia drug RE
U.S. FDA approves Akebia's anemia drug RE
Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis CI
Akebia Therapeutics, Inc. Announces Management Changes, Effective March 22, 2024 CI
Akebia Therapeutics, Inc. Announces Executive Changes, Effective March 22, 2024 CI
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q4 Revenue $56.2M, vs. Street Est of $55.4M MT
Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024 CI
Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Akebia Therapeutics, Inc. Secures $55 Million Term Loan Financing CI
Transcript : Akebia Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM
Akebia Therapeutics Names Nicholas Grund as Chief Commercial Officer MT
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer CI
Akebia Therapeutics, Inc. Announces the Appointment of Richard C. Malabre as Chief Accounting Officer and Principal Accounting Officer CI
HC Wainwright Adjusts Price Target on Akebia Therapeutics to $5 From $3.75, Maintains Buy Rating MT
Chart Akebia Therapeutics, Inc.
More charts
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.09 USD
Average target price
5 USD
Spread / Average Target
+358.72%
Consensus
  1. Stock Market
  2. Equities
  3. AKBA Stock
  4. News Akebia Therapeutics, Inc.
  5. Sector Update: Health Care Stocks Advance Premarket Thursday